Maexeni (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol and Levonorgestrel, the active ingredients in Maexeni, are a combined oral contraceptive presented as a tablet for oral use. It prevents pregnancy in women of reproductive age by inhibiting ovulation, altering cervical mucus, and regulating the endometrium effectively, providing reliable contraceptive protection when taken as directed.

GNH USA supplies Maexeni as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, through efficient logistics, ensuring quality‑assured products that meet European Union regulatory standards and supporting global healthcare delivery.

Maexeni, a combined oral contraceptive, is used to prevent pregnancy by modulating the hormonal axis that controls ovulation, cervical mucus consistency, and endometrial development, thereby providing a reliable method of birth control.

Prevention of pregnancy: Provides reliable contraceptive protection by suppressing ovulation, thickening cervical mucus, and inducing endometrial changes, effective when the tablet is taken daily at the same time as directed by a healthcare professional.

Contraceptive efficacy: Delivers over 99% pregnancy prevention with typical use, provided tablets are taken consistently at the same time each day.

Common Side Effects: - Nausea - Breast tenderness - Headache - Intermenstrual spotting - Weight gain - Mood changes

Serious or Rare Side Effects: - Venous thromboembolism (deep vein thrombosis, pulmonary embolism) - Arterial thrombosis (stroke, myocardial infarction) - Hypertension - Liver tumor (benign hepatic adenoma) - Severe allergic reaction (anaphylaxis) - Visual disturbances (blurred vision, retinal vein thrombosis)

Before prescribing Maexeni, clinicians should evaluate individual risk factors and contraindications. - Contraindicated in pregnancy: must not be used by pregnant women. - Avoid in smokers over 35 years: increased risk of thrombotic events. - Assess cardiovascular history: caution in patients with prior clotting disorders. - Monitor blood pressure regularly: oral contraceptives may elevate blood pressure. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Maexeni may interact with several medicines that alter hormone metabolism or increase clotting risk.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin) can reduce contraceptive efficacy. - Rifampin and other strong CYP3A4 inducers may lower hormone levels. - St. John’s Wort herbal supplement may diminish contraceptive effect.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., ketoconazole) may increase hormone concentrations, requiring monitoring. - Selective serotonin reuptake inhibitors can increase bleeding tendency. - Certain diuretics may affect fluid balance and blood pressure, necessitating observation.